Search Results: IdentityIQ-Engineer Sample Questions Answers πŸ›… Latest IdentityIQ-Engineer Mock Test πŸ”’ IdentityIQ-Engineer Exam PDF πŸ”± β–· www.pdfvce.com ◁ is best website to obtain β€œ IdentityIQ-Engineer ” for free download 🐴Sample IdentityIQ-Engineer Questions

[adbutler ad space=5]




Blog Post | News, Science + Research

Audentes Therapeutics Announces Plans to Develop Gene-Targeted Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

On April 8, Audentes Therapeutics announced that it will expand its gene-targeted therapy platform to include developing experimental drugs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).…

Tags: Antisense Oligonucleotide, Drug Development, Exon Skipping, Gene Therapy, Research


Blog Post | Personal Stories

A Tale of Two Siblings: Twin MDA Volunteers Forge Lifelong Connections β€” and Careers

Twin brother and sister Michael and Amy Schleicher’s story starts where a lot of kids’ stories do. They looked up to their big brother, Matt, and when he did something…

Tags: Community, MDA Care Centers, Muscle Walk, Summer Camp, Volunteers


Blog Post | News, Science + Research

Muscular Dystrophy Association Awards Eight Grants Totaling More Than $2 Million for ALS Research

Today, the Muscular Dystrophy Association (MDA) announced the awarding of eight new grants totaling more than $2 million toward research focused on amyotrophic lateral sclerosis (ALS), a disease in which…

Tags: Antisense Oligonucleotide, Drug Development, Gene Therapy, Grants, Research


Blog Post | News, Science + Research

Sarepta Therapeutics Announces Positive Interim Results from Study of Casimersen to Treat DMD Amenable to Exon 45 Skipping

OnΒ Mar. 28, Sarepta Therapeutics announced encouraging interim results from a phase 3 clinical trial that suggest the experimental drug casimersen potentially may be effective as a treatment for Duchenne muscular…

Tags: Clinical Trials, Drug Development, Exon Skipping, Gene Therapy


Blog Post | News, Science + Research

FDA Grants Orphan Drug Designation to Acceleron Pharma’s ACE-083 Muscle Growth Drug for Charcot-Marie-Tooth Disease

On Mar. 5, the U.S. Food and Drug Administration (FDA) awarded Orphan Drug designation to Acceleron Pharma’s ACE-083, a locally acting muscle agent, for treating Charcot-Marie-Tooth disease (CMT). Delivered by…

Tags: Clinical Trials, Drug Development, Research


Featured Article | Personal Stories

What Happened to You

A young man with SMA answers this question by becoming a student leader

Tags: College, From Where I Sit, Young Adults


Featured Article | Science + Research

News on LEMS Treatment and Research

A Q&A with researcher Stephen Meriney, Ph.D.

Tags: Drug Approval, Drug Development, Grants, Research


Featured Article | Inclusion, Independence, Lifestyle

Making the Workplace Accessible

Think outside the cubicle to find solutions to common accessibility challenges in the office

Tags: Employment


Featured Article | Health, Independence

Prepare Yourself

In the face of the everchanging medical landscape, it is important that you prepare yourself and family members to go to the emergency room alone or without the option of…

Tags: Featured Content, Healthcare


Featured Article | Inclusion, Independence, Lifestyle

The Independent Mindset

When neuromuscular disease impacts your ability to perform daily tasks, cultivating problem-solving skills and support can help you live independently in your home

Tags: College, Featured Content, MDA Resource Center, Personal Care Attendants, Resources, Young Adults